Clozapine Tablets

This product is a dibenzodiazepine antipsychotic. It has a strong blocking effect on the 5-hydroxytryptamine (5-HT2A) receptors and dopamine (DA1) receptors in the brain, and also has a blocking effect on the dopamine (DA4) receptors. The blocking effect on the dopamine (DA2) receptor is weaker. In addition, it has anticholinergic (M1), antihistamine (H1) and anti-a-adrenaline receptor effects. Extrapyramidal reactions are rare and generally do not cause an increase in blood prolactin. It can directly inhibit the ascending activation system of the brainstem reticular formation and has a strong sedative and hypnotic effect.

The main ingredient of this product is clozapine. Its chemical name is 8-chloro-11-(4-methyl-1-piperazine)-5H-dibenzo[b,e][1,4]diazepine. Molecular formula: C18H19ClN4 Molecular weight: 326.84

This product is a light yellow tablet

This product is not only effective for the positive symptoms of psychosis, but also has a certain effect on the negative symptoms. It is suitable for various subtypes of acute and chronic schizophrenia, and has good effects on hallucination and delusional types and adolescent types. It can also alleviate the emotional symptoms associated with schizophrenia (such as depression, guilt, anxiety). For some patients who are ineffective or have poor therapeutic effects with traditional antipsychotic drugs, switching to this product may be effective. This product is also used to treat excitement, agitation and hallucinations and delusions in mania or other psychotic disorders. Because it causes neutropenia, it is generally not suitable as the first choice drug.

Oral administration starts with a small dose, the first dose is 25 mg (1 tablet) at a time, 2 to 3 times a day, and gradually increases slowly to the commonly used therapeutic dose of 200 to 400 mg a day (8 to 16 tablets), and the highest dose can reach 600 mg a day (24 tablets). The maintenance dose is 100 to 200 mg a day (4 to 8 tablets).

1. Strong sedative and anticholinergic adverse reactions, common ones include dizziness, weakness, drowsiness, sweating, salivation, nausea, vomiting, dry mouth, constipation, postural hypotension, and tachycardia. 2. Increased appetite and weight gain are common. 3. Can cause abnormal electrocardiogram changes. Can cause electroencephalogram changes or epileptic seizures. 4. Can also cause increased blood sugar. 5. Serious adverse reactions include agranulocytosis and secondary infection.

It is contraindicated for patients with severe heart, liver, or kidney disease, coma, delirium, hypotension, epilepsy, glaucoma, bone marrow suppression, or leukopenia. It is contraindicated for patients who are allergic to this product.

Precautions for children: Not suitable for children under 12 years old. Precautions for pregnancy and lactation: Contraindicated for pregnant women. Lactating women should stop breastfeeding while using this product. Precautions for the elderly: Use with caution or use low doses.

1. This product can increase the central nervous system depression effect when used in combination with ethanol or other central nervous system depressants. 2. This product can increase the risk of orthostatic hypotension when used in combination with antihypertensive drugs. 3. This product can increase the anticholinergic effect when used in combination with anticholinergic drugs. 4. This product can increase the bone marrow suppression effect when used in combination with digoxin, heparin, phenytoin, and warfarin. 5. This product can increase the risk of convulsions, malignant syndrome, delirium, and dystonia when used in combination with lithium carbonate. 6. This product can increase the plasma clozapine and norclozapine levels when used in combination with antidepressants such as fluvoxamine, fluoxetine, paroxetine, and sertraline. 7. This product can significantly increase the plasma clozapine concentration when used in combination with macrolide antibiotics, and there are reports of inducing epileptic seizures.

Shade, sealed and stored

25 mg

48 months

Beijing Yimin Pharmaceutical Co., Ltd.

• Founded in:

  1981-01-31

• Address:

  North of Yongjun Road, Shunyi District, Beijing

• Tax NO.:

  91110113102531398L

• Registered Funds:

  5.18 million yuan

• Website:

  Log in to view

• Email:

  Log in to view